Home drugs Avastin (Bevacizumab)

Avastin (Bevacizumab)

This page contains brief information about bevacizumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Bevacizumab is approved to be used alone or with other drugs to treat:

  • Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back).
  • Colorectal cancer that has metastasized.
  • Glioblastoma (a type of brain cancer). It is used in adults whose:
    • Cancer has recurred. This use is approved for the Avastin brand of bevacizumab.
    • Cancer got worse after other treatment. This use is approved for the Mvasi brand of bevacizumab.
  • Nonsquamous non-small cell lung cancer that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred.
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used in patients with stage III, stage IV, or recurrent disease. This use is approved for the Avastin brand of bevacizumab.
  • Renal cell carcinoma (a type of kidney cancer) that has metastasized.

Bevacizumab is also being studied in the treatment of other types of cancer.

More About Bevacizumab

MedlinePlus Information on Bevacizumab – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied